Enalapril Maleate (C09-0880-547)

InformationEnalapril (MK-421) Maleate is anangiotensin-converting enzyme (ACE)inhibitor, used in the treatment of hypertension, diabetic nephropathy, and chronic heart failure.In vitroEnalapril/xa0is rapidly converted by ester hydrolysis to enalaprilat, a potent ACE/xa0inhibitor;/xa0Enalapril/xa0itself is only a weak ACE/xa0inhibitor./xa0Enalapril/xa0lowers peripheral vascular resistance without causing an increase in heart rate./xa0In vivoEnalapril/xa0treatment/xa0abolishes the deleterious effects of/xa0eNOS/xa0deficiency on blood pressure (BP),/xa0atherosclerosis, and/xa0kidney dysfunction/xa0in nnee/xa0mice. Enalapril/xa0causes a dose-dependent increase in fore limb strength/xa0in the/xa0mdx/xa0mouse. Enalapril/xa0causes a dose-dependent reduction of superoxide anion production/xa0in tibialis anterior/xa0muscle/xa0of the/xa0mdx/xa0mouse as observed by dihydroethidium staining./xa0Enalapril/xa0(5 mg/kg) reduces the area of/xa0muscle/xa0necrosis in both gastrocnemious/xa0muscle/xa0and diaphragm, without significant effect on non-muscle/xa0area. Enalapril Maleate results in significant increases in kidney weight and in concentrations of urinary albumin, N-acetyl-fl-d-glucosamidase (NAG) and serum ET-1 in streptozotocin (STZ)-induced/xa0diabetic (STZ-DM)/xa0rats as compared with the non-diabetic/xa0rats, and the concentration of ET-1 in the kidneys tended to be increased. Enalapril Maleate results in increased mesangial cell proliferation, matrix expansion and enlarged mesangial area in the kidney of the/xa0diabetic/xa0rats./xa0Enalapril Maleate reduces increased concentrations of urinary albumin and NAG in the STZ-DM/xa0rats to the control values with a slight improvement in the electron microscopic/xa0changes.Cell Datacell lines：Concentrations：Incubation Time：Powder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C20H28N2O5·C4H4O4 Molecular Weight: 492.52